Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Opening Session Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Mar
09
Today In Oncology
Activity Observed with Novel KRAS Inhibitor in Pancreatic Cancer
AI-Backed Liquid Biopsies Identify Liver Diseases
Peter WT Pisters Honored With Top Award From Society of Surgical Oncology
TACE With Camrelizumab and Rivoceranib in Unresectable Hepatocellular Carcinoma
Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo